drug adverse effects of atypical antipsychotic agents

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]

Adverse effects

  • hyperglycemia; increased risk of diabetes[2] (may be all atypical antipsychotics)[2]

Hazard ratios for development of diabetes mellitus:[3]

 clozapine    1.57
 quetiapine   1.20
 olanzapine   1.15
 respiridone  1.01

* RR in demented patients

More general terms

References

  1. ↑ UCLA Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
  2. ↑ 2.0 2.1 2.2 Prescriber's Letter 10(11):62 2003
  3. ↑ 3.0 3.1 Journal Watch 24(21):160, 2004 Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004 Sep;161(9):1709-11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15337666
  4. ↑ 4.0 4.1 Rovner BW, German PS, Broadhead J, Morriss RK, Brant LJ, Blaustein J, Folstein MF. The prevalence and management of dementia and other psychiatric disorders in nursing homes. Int Psychogeriatr. 1990 Spring;2(1):13-24. PMID: https://www.ncbi.nlm.nih.gov/pubmed/2101294
  5. ↑ 5.0 5.1 5.2 Schneeweiss S et al, Risk of death with use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007, 176:627 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17325327
  6. ↑ 6.0 6.1 Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, Blow FC. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007 Oct;164(10):1568-76. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17898349
  7. ↑ 7.0 7.1 7.2 Rochon PA et al, Antipsychotic Therapy and Short-term Serious Events in Older Adults With Dementia Arch Intern Med 2008 168(10) PMID: https://www.ncbi.nlm.nih.gov/pubmed/18504337
  8. ↑ 8.0 8.1 FDA Public Health Advisory Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances http://www.fda.gov/cder/drug/advisory/antipsychotics.htm http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#atypical
    FDA MedWatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#Antipsychotics Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005 Oct 19;294(15):1934-43. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16234500
  9. ↑ Douglas IJ and Smeeth L. Exposure to antipsychotics and risk of stroke: Self controlled case series study. BMJ 2008 Aug 28; 337:a1227. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18755769
  10. ↑ 10.0 10.1 Ray WA et al, Atypical antipsychotic drugs and the risk of sudden cardiac death. NEJM 2009, 360:225 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19144938
  11. ↑ 11.0 11.1 Correll CU et al Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents JAMA. 2009;302(16):1765-1773 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/19861668 <Internet> http://jama.ama-assn.org/cgi/content/short/302/16/1765
    Varley CK & McClellan J Implications of Marked Weight Gain Associated With Atypical Antipsychotic Medications in Children and Adolescents JAMA. 2009;302(16):1811-1812 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/19861677 <Internet> http://jama.ama-assn.org/cgi/content/short/302/16/1811
  12. ↑ 12.0 12.1 FDA MedWatch Feb 22, 2011 Antipsychotic drugs: Class Labeling Change - Treatment During Pregnancy and Potential Risk to Newborns http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm244175.htm
  13. ↑ 13.0 13.1 13.2 13.3 Geriatric Review Syllabus, 7th edition Parada JT et al (eds) American Geriatrics Society, 2010
    Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
  14. ↑ 14.0 14.1 14.2 Huybrechts KF et al Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study BMJ 2012;344:e977 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22362541 <Internet> http://www.bmj.com/content/344/bmj.e977
    McCleery J and Fox R Antipsychotic prescribing in nursing homes BMJ 2012;344:e1093 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22362540 <Internet> http://www.bmj.com/content/344/bmj.e1093
  15. ↑ 15.0 15.1 Romo-Nava F et al. Melatonin attenuates antipsychotic metabolic effects: An eight-week randomized, double-blind, parallel-group, placebo- controlled trial. Bipolar Disord 2014 Mar 17 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24636483 <Internet> http://onlinelibrary.wiley.com/doi/10.1111/bdi.12196/abstract
  16. ↑ 16.0 16.1 Vigen CL, Mack WJ, Keefe RS et al Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry. 2011 Aug;168(8):831-9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21572163
  17. ↑ 17.0 17.1 17.2 Hwang YJ, Dixon SN, Reiss JP et al Atypical Antipsychotic Drugs and the Risk for Acute Kidney Injury and Other Adverse Outcomes in Older Adults: A Population-Based Cohort Study. Ann Intern Med. 2014;161(4):242-248 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25133360 <Internet> http://annals.org/article.aspx?articleid=1897100
  18. ↑ 18.0 18.1 Fraser LA et al. Falls and fractures with atypical antipsychotic medication use: A population-based cohort study. JAMA Intern Med 2015 Jan 12 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25581312 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=2089230
  19. ↑ 19.0 19.1 Weintraub D et al. Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol 2016 Mar 21 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26999262
  20. ↑ 20.0 20.1 NEJM Knowledge+ Endocrinology
Retrieved from "https://aaushi.info/w/index.php?title=A24938&oldid=1203762"